Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

BACKGROUND: New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquili...

Descripción completa

Detalles Bibliográficos
Autores principales: Tweed, Conor D, Dawson, Rodney, Burger, Divan A, Conradie, Almari, Crook, Angela M, Mendel, Carl M, Conradie, Francesca, Diacon, Andreas H, Ntinginya, Nyanda E, Everitt, Daniel E, Haraka, Frederick, Li, Mengchun, van Niekerk, Christo H, Okwera, Alphonse, Rassool, Mohammed S, Reither, Klaus, Sebe, Modulakgotla A, Staples, Suzanne, Variava, Ebrahim, Spigelman, Melvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641992/
https://www.ncbi.nlm.nih.gov/pubmed/31732485
http://dx.doi.org/10.1016/S2213-2600(19)30366-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641992/
https://www.ncbi.nlm.nih.gov/pubmed/31732485
http://dx.doi.org/10.1016/S2213-2600(19)30366-2

Ejemplares similares